Allergan (NYSE:AGN) to Host R&D Technology Review June 4

Allergan (NYSE:AGN) will host a Research and Development Technology Review on Wednesday, June 4 at 1:00 pm ET.  A live webcast of the event will be available at allergen.com.

Allergan, Inc. is a multi-specialty healthcare company focused on developing and commercializing pharmaceuticals, biologics and medical devices. The Company discovers, develops and commercializes specialty pharmaceutical, medical device and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatological, breast aesthetics, obesity intervention, urological, and other specialty markets in more than 100 countries around the world.

In January 2007, Allergan, Inc. acquired all of the outstanding capital stock of Groupe Corneal Laboratoires (Corneal), a healthcare company that develops, manufactures and markets dermal fillers, viscoelastics, and a range of ophthalmic surgical device products. In October 2007, the Company acquired all of the outstanding capital stock of Esprit Pharma Holding Company, Inc. (Esprit). Allergan, Inc. operates in two business segments: specialty pharmaceuticals and medical devices.

Find more Conference Calls on Finditt Events.